December 4, 2016 08:50 AM EST
R&D

#ASH16: Pfiz­er of­fers a thumbs-up on OS da­ta from PhII blood can­cer study of glas­deg­ib

John Carroll

Editor & Founder

Pfiz­er came up with some solid­ly pos­i­tive Phase II da­ta for a new drug that’s de­signed to throw a mon­key wrench in­to the bi­ol­o­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

Roche ini­tial­ly did­n't want to buy Po­sei­da — and part­ner Astel­las did­n't sub­mit an of­fer, new fil­ings show

J&J, Leg­end’s Carvyk­ti clears a type of blood can­cer in ‘nine out of 10’ pa­tients

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times